Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).
Caldera Therapeutics has raised $37.5M in total funding. The most recent round was Series A. The last funding was announced in January 2026.
Caldera Therapeutics's investors include Lilly Asia Ventures, Janus Henderson Investors, Wellington Management, Omega Funds, Atlas Venture.
Caldera Therapeutics is headquartered in Cambridge, United States.
Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).
Caldera Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Caldera Therapeutics — Funding & Investors." VCBacked, January 14, 2026, https://www.vcbacked.co/company/caldera-therapeutics. Accessed September 29, 2026.
VCBacked. (2026). Caldera Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/caldera-therapeutics
{{cite web |title=Caldera Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/caldera-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated